US EditionAstraZeneca Sees a 44% Drop in Breast Cancer Progression with Its Drug Enhertu
Summary by 14ymedio.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Progression-free survival was elevated to 40.7 months in the treatment group, compared to 26.9 months in the standard solution
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
